Aclarion, Inc., a commercial-stage healthcare technology company, has published a shareholder letter from CEO Brent Ness outlining the company's strategic priorities and catalysts for 2026. The letter highlights the company's focus on expanding adoption of its Nociscan platform, which uses biomarkers and augmented intelligence algorithms to help physicians identify the location of chronic low back pain.
The company's 2026 priorities include pursuing reimbursement coverage from regional insurance providers in the United States, which represents an important step toward broader payer adoption. Aclarion is also advancing reimbursement initiatives in both the United Kingdom and the United States while expanding commercial engagement with physicians and imaging centers. The full CEO Shareholder Letter is available on the company's website at https://www.aclarion.com.
A key catalyst for 2026 is the initial readout from the CLARITY clinical trial expected in the fourth quarter of 2026. This trial represents important clinical evidence for the Nociscan technology, which is described as the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology leverages Magnetic Resonance Spectroscopy data processed through proprietary algorithms to indicate if a disc may be a source of pain.
CEO Brent Ness stated that the company's focus remains on disciplined execution against key catalysts that can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of the business. "With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders," Ness said in the letter.
The company reports a strong balance sheet with cash runway extending into 2028, providing financial stability to support continued execution of its strategic initiatives. This financial position is particularly important as the company navigates the regulatory and commercialization landscape for medical technology. For more News from Aclarion, please visit: https://tinyurl.com/aconnewsroom.
The importance of Aclarion's progress lies in addressing the significant market for chronic low back pain, a condition affecting millions of people worldwide. Current diagnostic approaches often struggle to precisely identify pain sources, leading to suboptimal treatment outcomes. Nociscan's technology aims to provide physicians with clearer insights into pain location, potentially enabling more targeted and effective treatment strategies. The company's reimbursement efforts represent a critical step toward making this technology more accessible to patients through insurance coverage.
The clinical trial results expected in late 2026 will provide important validation data that could influence both medical adoption and payer decisions. As healthcare systems increasingly seek evidence-based technologies that can improve outcomes while potentially reducing costs through more accurate diagnoses, Aclarion's progress in 2026 could have implications for how chronic pain is diagnosed and treated. The company's Nasdaq listing (ACON, ACONW) also means its strategic execution has implications for healthcare technology investors monitoring innovations in pain management diagnostics.
